麝香保心丸对急性心肌梗死血管新生作用的研究进展

doi:10.19739/j.cnki.issn1001-9510.2020.06.016

Abstract
Figure/Table
References
Related Citation (3)

Download: PDF (1010 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Acute myocardial infarction (AMI) is due to the acute and continuous decrease of blood flow in the coronary artery, which leads to the injury of myocardial hypoxia. AMI has the characteristics of rapid onset, rapid progress, high mortality and serious threat to human life and health. Shexiang baoxin pill (SBP) is a kind of Chinese patent drug composed of artificial musk, ginseng extract, artificial bezoar, cinnamon, Styrax, toad and borneol. It plays an important role in the treatment of unstable angina pectoris and myocardial infarction. Therapeutic angiogenesis is a promising concept, which can promote the angiogenesis of endogenous collateral vessels, restore myocardial blood supply, reduce infarct area and improve cardiac function after myocardial infarction. In recent years, the effect of Shexiang baoxin pill on the angiogenesis of acute myocardial infarction has been recognized and valued by people. Now, the effect of Shexiang naoxin pill on the angiogenesis of acute myocardial infarction is reviewed to provide reference for the clinical treatment of AMI.

Key words： shexiang baoxin pill acute myocardial infarction angiogenesis

Received: 01 September 2020

PACS:

R542.2+2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DU Xin
	LIU Changmei
	DONG Binchang
	ZHAI Miaobo
	XU Huipu

Cite this article:

DU Xin,LIU Changmei,DONG Binchang, et al. Research progress of shexiang baoxin pill on angiogenesis of acute myocardial infarction[J]. 滨州医学院学报, 2020, 43(6): 457-460.

URL:

http://manu58.magtech.com.cn/Jwk_bzyxy/EN/10.19739/j.cnki.issn1001-9510.2020.06.016 OR http://manu58.magtech.com.cn/Jwk_bzyxy/EN/Y2020/V43/I6/457

[1] ROTH G A,JOHNSON C,ABAJOBIR A,et al.Global,regional,and national burden of cardiovascular diseases for 10 Causes,1990 to 2015[J].J Am Coll Cardiol,2017,70(1):1-25.
[2] 马丽媛,吴亚哲,王文,等.《中国心血管病报告2017》要点解读[J].中国心血管杂志,2018,23(1):3-6.
[3] ZHAO D.Why dentists need to learn the epidemiological status and prevention strategy of coronary heart disease in China[J].Zhonghua Kou Qiang Yi Xue Za Zhi,2016,51(7):385-386.
[4] 张现朝,侯亚敏,欧知宏.冠脉造影术评价麝香保心丸对冠状动脉的扩张作用[J].中国中西医结合杂志,2014,34(12):1432-1435.
[5] 吴建祥,梁春,任雨笙,等.麝香保心丸对内皮祖细胞功能及分泌一氧化氮的影响[J].中国中西医结合杂志,2009,29(6):511-513.
[6] ZHANG J,CUI Q,ZHAO Y,et al.Mechanism of angiogenesis promotion with Shexiang Baoxin Pills by regulating function and signaling pathway of endothelial cells through macrophages[J].Atherosclerosis,2020,292:99-111.
[7] LV C,CHEN L,FU P,et al.Simultaneous quantification of 11 active constituents in Shexiang Baoxin Pill by ultraperformance convergence chromatography combined with tandem mass spectrometry[J].Chromatogr B Analyt Technol Biomed Life Sci,2017,1052:135-141.
[8] LIU Q,LV C,ZHANG W D,et al.Advance in modern studies on Shexiang Baoxin Pill[J].Chin Tradit Herbs Drug,2016,47:1409-1417.
[9] 宋华.麝香保心丸的药理研究与临床评价[J].中成药,2002,24(2):131-133.
[10] WEN J,MA X,ZHANG L,et al.Therapeutic efficacy and safety of Shexiang Baoxin Pill combined with trimetazidine in elderly patients with heart failure secondary to ischaemic cardiomyopathy: A systematic review and meta-analysis[J].Medicine(Baltimore),2018,97(51):e13580.
[11] 何扳龙,郭和,杨光宝,等.麝香保心丸治疗冠心病心绞痛72例疗效观察[J].中国当代医药,2009,16(14):66-67.
[12] 沈琴.麝香保心丸治疗冠心病心绞痛患者的效果研究[J].中西医结合心血管病电子杂志,2018,6(35):165-166.
[13] 贺明清,陈小钦,谢秩芬.麝香保心丸联合单硝酸异山梨酯缓释片治疗冠心病心绞痛的疗效观察[J].现代药物与临床,2018,33(7):1608-1612.
[14] WEI D,ZHENG N,ZHENG L,et al.Shexiang Baoxin Pill CorrectsMetabolic Disorders in a Rat Model of Metabolic Syndrome by Targeting Mitochondria[J].Front Pharmacol,2018,9:137.
[15] 李天奇,李勇,范维琥.麝香保心丸和辛伐他汀对兔股动脉粥样硬化斑块稳定性的影响[J].中华老年心脑血管病杂志,2006(5):296-299.
[16] LU LI,QIN YATING,ZHANG XINXIN,et al.Shexiang Baoxin Pill Alleviates the Atherosclerotic Lesions in Mice via Improving Inflammation Response and Inhibiting Lipid Accumulation in the Arterial Wall[J].Mediators of inflammation,2019,2019.
[17] 王丽洁,罗心平,王涌,等.长期口服麝香保心丸改善冠心病病人血管内皮功能的临床研究[J].中西医结合心脑血管病杂志,2008(2):129-131.
[18] 刘群,吕超,张卫东,等.麝香保心丸研究进展[J].中草药,2016,47(8):1409-1417.
[19] BADIMON L,BORRELL M.Microvasculature Recovery by Angiogenesis After Myocardial Infarction[J].Curr Pharm Des,2018,24(25):2967-2973.
[20] CARMELIET P,JAIN R K.Molecular mechanisms and clinical applications of angiogenesis[J].Nature,2011,473:298-307.
[21] 金惠铭,李先涛.血管新生的调控[J].中国微循环,2001,5(2):85-88.
[22] BADIMON L,BORRELL M.Microvasculature Recovery by Angiogenesis After Myocardial Infarction[J].Curr Pharm Des,2018,24(25):2967-2973.
[23] CARMELIET P,JAIN R K.Molecular mechanisms and clinical applications of angiogenesis[J].Nature,2011,473:298-307.
[24] FARBER A,EBERHARDT R T.The Current State of Critical Limb Ischemia: A Systematic Review[J].JAMA Surg,2016,151(11):1070-1077.
[25] SCHREVE M A,VOS C G,VAHL A C,et al.Venous Arterialisation for Salvage of Critically Ischaemic Limbs: A Systematic Review and Meta-Analysis[J].Eur J Vasc Endovasc Surg,2017,53(3):387-402.
[26] LIAO Q,QU S,TANG L X,et al.Irisin exerts a therapeutic effect against myocardial infarction via promoting angiogenesis[J].Acta Pharmacol Sin,2019,40(10):1314-1321.
[27] HU M S,WALMSLEY G G,BARNERS L A,et al.Delivery of monocyte lineage cells in a biomimetic scaffold enhances tissue repair[J].JCI Insight,2017,2(19):e96260.
[28] BRIDGES E,HARRIS A L.Vascular-Promoting Therapy Reduced Tumor Growth and Progression by Improving Chemotherapy Efficacy[J].Cancer Cell,2015,27(1):7-9.
[29] SHEN J,JI Y,XIE M,et al.Cell-modified bioprinted microspheres for vascular regeneration[J].Mater Sci Eng C Mater Biol Appl,2020,112:110896.
[30] FANG H Y,ZENG H W,LIN L M,et al.A network-based method for mechanistic investigation of Shexiang Baoxin Pill's treatment of cardiovascular diseases[J].Sci Rep,2017,7:43632.
[31] 朱慧,罗心平,王丽洁,等.长期服用麝香保心丸治疗冠心病临床疗效评价[J].中国中西医结合杂志,2010,30(5):474-477.
[32] HUANG H,YANG Y,LV C,et al.Pharmacokinetics and tissue distribution of five bufadienolides from the Shexiang Baoxin Pill following oral administration to mice[J].Ethnopharmacol,2015,161:175-185.
[33] JIANG P,DAI W,YAN S,et al.Biomarkers in the early period of acute myocardial infarction in rat serum and protective effects of Shexiang Baoxin Pill using a metabolomic method[J].Journal of ethnopharmacology,2011,138(2):530-536.
[34] ZHOU Z,SHEN W,YU L,et al.A Chinese patent medicine,Shexiang Baoxin Pill,for Non-ST-elevation acute coronary syndromes: A systematic review[J].Ethnopharmacol,2016,194:1130-1139.
[35] 汪姗姗,李勇,范维琥,等.麝香保心丸对鸡胚绒毛尿囊膜及培养的血管内皮细胞的促血管生成作用[J].中国中西医结合杂志,2003,23(2):128-131.
[36] 吕超,黄慧梅,畅婉琳,等.麝香保心丸促进血管新生作用的活性成分筛选[J].药学实践杂志,2014,32(5):344-347.
[37] 赵春晓.麝香保心丸对冠状动脉粥样硬化性心脏病(冠心病)血管内皮功能的影响[J].中医临床研究,2019,11(15):32-33.
[38] HUANG F,LIU Y,YANG X,et al.Shexiang Baoxin pills promotes angiogenesis in myocardial infarction rats via up-regulation of 20-HETE-mediated endothelial progenitor cells mobilization[J].Atherosclerosis,2017,263:184-191.
[39] ZHANG J,CUI Q,ZHAO Y,et al.Mechanism of angiogenesis promotion with Shexiang Baoxin Pills by regulating function and signaling pathway of endothelial cells through macrophages[J].Atherosclerosis,2020,292:99-111.